Histone deacetylase HDAC7 restricts CD8 + T cell tumor infiltration and limits immunotherapy sensitivity in bladder cancer: reversal by pinocembrin
HDAC7 represents a promising diagnostic and therapeutic target in BCa immunotherapy. Pinocembrin, as a specific HDAC7 inhibitor, holds potential as a combination therapy agent to improve immunotherapy response in BCa.
Authors
- Ruixi Yu
- B. Liu
- Jiancheng Lv (ORCID: https://orcid.org/0000-0002-7698-8938)
- Qiang Lu
- Jiatong Zhou
- Kai Li
Institutions
- Jiangnan University (CN)
- Zhejiang Cancer Hospital (CN)
- Second Affiliated Hospital of Nanjing Medical University (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-12-24
- DOI
- https://doi.org/10.1186/s13046-025-03585-3
- Primary Topic
- Histone Deacetylase Inhibitors Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China